23andMe Investor Presentation Deck

1 23andMe's Value Proposition Disrupting the Healthcare experience. 23andMe is building a personalized health and wellness experience that caters uniquely to the individual by harnessing the power of their DNA. Integrating Lemonaid Health's online digital health platform to deliver personalized, prevention-oriented, genetically- based healthcare at scale The world's premier re-contactable phenotype-linked genetic database. A vast (>12M genotyped 2 customers) proprietary dataset rich with both genotypic and phenotypic (health) information allows insights that unlock revenue streams across digital health, therapeutics, and much more Continuously increasing quantity and quality of phenotypic data. Impressive customer participation 3 provides >4 billion phenotypic data points for unprecedented statistical power to discover new insights into health and potential therapies. Over 40 identified therapeutics programs validates the approach of developing novel therapeutics 4 using genetic data. One program in clinical development with GSK, one wholly owned program started clinical trials in January 2022. Difficult to replicate platform for value creation. The FDA-approved consumer platform, the 5 therapeutics efforts, and the rich database combine to create multiple opportunities for substantial value creation 6 Strong cash position. Strong balance sheet supports 23and Me's plans for significant investment in therapeutics portfolio and strategic initiatives Copyright © 2022 23and Me, Inc. 23andMe 63

View entire presentation